15.6 C
New York
Friday, September 29, 2023

Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) Could Achieve Gains In The Near Future

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Vertex Pharmaceuticals Incorporated (VRTX) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.42, or 0.12%, to $352.42. The Vertex Pharmaceuticals Incorporated has recorded 22,533 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Vertex Receives CHMP Positive Opinion for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor for Children With Cystic Fibrosis Ages 2 Through 5.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Stocks Info

Vertex Pharmaceuticals Incorporated is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Vertex Pharmaceuticals Incorporated is $90.98B. A total of 0.63 million shares were traded on the day, compared to an average of 1.07M shares.

Insider Activity

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, VRTX has seen 2 BUY and 9 SELL insider trades, representing the acquisition of 21,250 and the disposition of 45,164 shares. Over the last 12 months, there were 50 BUYs and 220 SELLs from insiders. Insiders purchased 459,095 shares during that period but sold 372,159.

In the most recent transaction, Bozic Carmen sold 5,651 shares of VRTX for 352.66 per share on Sep 05. After the transaction, the EVP and CMO now owns 57,556 company shares. In a previous transaction on Aug 23, Tatsis Ourania sold 2,500 shares at 355.00 per share. VRTX shares that EVP, Chief Reg. & Quality Off. owns now total 48,637.

Among the insiders who sold shares, Sachdev Amit disposed of 10,031 shares on Aug 10 at a per-share price of $350.00. This resulted in the EVP, Chief Patient Officer holding 58,814 shares of VRTX after the transaction. In another insider transaction, Kearney Terrence C sold 10,000 shares at $350.00 per share on Aug 10. Company shares held by the Director now total 6,536.


The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. VRTX’s most recent ex-dividend date was when it declared a $0.40 quarterly dividend that was paid in cash on 3/13/2013.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for VRTX in the last 3 months, the mean price target is $386.81 with high estimates of $456.00 and low estimates of $315.00. In terms of 52-week highs and lows, VRTX has a high of $367.00 and a low of $276.57.

As of this writing, VRTX has an earnings estimate of $Vertex Pharmaceuticals Incorpor per share for the current quarter. EPS was calculated based on a consensus of RTX Corporation estimates, with a high estimate of $Vertiv Holdings, LLC per share and a lower estimate of $Viking Therapeutics, Inc.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. VRTX’s latest balance sheet shows that the firm has $7.52B in Cash & Short Term Investments as of fiscal 2021. There were $556.70M in debt and $1.87B in liabilities at the time. Its Book Value Per Share was $60.03, while its Total Shareholder’s Equity was $10.10B.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for VRTX is Buy with a score of 4.42.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles